OncoMatch/Clinical Trials/NCT06541444
Safety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid Leukemia
Is NCT06541444 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies NK520 for relapsed/refractory acute myeloid leukemia.
Treatment: NK520 — This study will evaluate the safety and efficacy of NK520 in the treatment of relapsed/refractory acute myeloid leukemia. NK520 will be administered by intravenous injection. The safety and efficacy of this treatment will be evaluated.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Lab requirements
Blood counts
Normal Organ Function
Kidney function
Normal Organ Function
Liver function
Normal Organ Function
Normal Organ Function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06541444 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages